An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

A new artificial intelligence model developed by Stanford Medicine combines clinical notes and pathology images to predict ...

Researchers at the University of Houston are harnessing artificial intelligence to enhance cancer treatments by customizing ...